These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22113150)

  • 21. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
    Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
    Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
    Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM
    HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
    Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
    Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.
    Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP
    Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arterial stiffness profiles: investigating various sections of the arterial tree of African and Caucasian people.
    Schutte AE; Huisman HW; Schutte R; Van Rooyen JM; Malan L; Malan NT; Reimann M
    Clin Exp Hypertens; 2011; 33(8):511-7. PubMed ID: 21958364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
    Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
    Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-terminal prohormone B-type natriuretic peptide and cardiovascular function in Africans and Caucasians: the SAfrEIC study.
    Kruger R; Schutte R; Huisman HW; Hindersson P; Olsen MH; Schutte AE
    Heart Lung Circ; 2012 Feb; 21(2):88-95. PubMed ID: 22119736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
    Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
    J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery?
    Schultz-Swarthfigure CT; McCall P; Docking R; Galley HF; Shelley B
    Interact Cardiovasc Thorac Surg; 2021 Jan; 32(2):236-243. PubMed ID: 33236082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a physical activity intervention on suPAR levels: A randomized controlled trial.
    Rohde C; Polcwiartek C; Andersen E; Vang T; Nielsen J
    J Sci Med Sport; 2018 Mar; 21(3):286-290. PubMed ID: 28728886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia?
    Sunnetcioglu A; Sunnetcioglu M; Adıyaman F; Binici I; Soyoral L
    Clin Respir J; 2017 Nov; 11(6):925-930. PubMed ID: 26683264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.
    Okulu E; Arsan S; Akin IM; Ates C; Alan S; Kilic A; Atasay B
    J Clin Lab Anal; 2015 Sep; 29(5):347-52. PubMed ID: 25043869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
    Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M
    Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
    Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
    Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
    Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
    Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.